Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|April 13, 2012
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomesJanneke Jentink, Cornelis Boersma, Lolkje T W de Jong-van den Berg, et al.
Pharmacoepidemiology and Drug Safety|September 29, 2011
Evaluation of the representativeness of a Dutch non-malformed control group for the general pregnant population: are these controls useful for EUROCAT?Janneke Jentink, A Priscilla Zetstra-van der Woude, Jens Bos, et al.
Pharmacoepidemiology and Drug Safety|August 4, 2010
Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?Janneke Jentink, Marian K Bakker, Cynthia M Nijenhuis, et al.
European Journal of Public Health|February 2, 2008
Economic evaluation of folic acid food fortification in The NetherlandsJanneke Jentink, Nienke W van de Vrie-Hoekstra, Lolkje T W de Jong-van den Berg, et al.
BMJ (Clinical Research Ed.)|December 4, 2010
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control studyJanneke Jentink, Helen Dolk, Maria A Loane, et al.
The New England Journal of Medicine|June 19, 2010
Valproic acid monotherapy in pregnancy and major congenital malformationsJanneke Jentink, Maria A Loane, Helen Dolk, et al.
The Journal of Rheumatology|July 5, 2011
The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general populationHubertina J M J Crijns, Janneke Jentink, Ester Garne, et al.
Pageof 1